ChinaBio® Partnering Forum 2017: ConSynance tests waters in China with differentiated NASH asset

June 5, 2017
Dr. Shuang Liu, president and co-founder of upstate New York-based ConSynance Therapeutics discusses with Scrip’s Brian Yang the startup's plan to develop and commercialize its multiple assets in various stages. Armed with years of experience developing assets working at Albany Medical Research Inc. for big pharma like BMS, Shuang Liu and her business partner struck out on their own and founded ConSynance. Now they have multiple assets in different stages, targeting NASH, fibrosis, central nerve system (CNS), diabetes and irritable bowel syndrome. The company also collaborates with Albany Medical College for diabetes and obesity treatment, and owns the rights to a novel treatment for IBS targeting 5-HT3 receptor. This interview was recorded at ChinaBio® Partnering Forum organized by EBD Group and ChinaBio® Group in Zhuhai, Guangdong, in May 2017.
Previous Video
ChinaBio® Partnering Forum 2017: China's EpimAb hunts for novel biologics with funding, partnership
ChinaBio® Partnering Forum 2017: China's EpimAb hunts for novel biologics with funding, partnership

Dr. Wu Chengbin, CEO and founder of Shanghai-based EpimAb Biotherapeutics discusses with Scrip’s Brian Yang...

Next Video
ChinaBio® Partnering Forum 2017: Funding drug development in China through VCs and partnerships
ChinaBio® Partnering Forum 2017: Funding drug development in China through VCs and partnerships

Western and China companies are leveraging the significant funding and support available in China to develo...